What is MetronomX?
MetronomX is a biopharmaceutical company dedicated to improving the quality and outcomes of cancer treatment through the development of innovative medicines. The company's pipeline includes two primary products, MNX-100 and MNX-200, which are currently undergoing clinical development. MetronomX's focus is on serving patients undergoing cancer treatment and advancing medical science via its research initiatives. The organization also highlights the critical role of clinical trial enrollment in furthering its mission.
How much funding has MetronomX raised?
MetronomX has raised a total of $4M across 1 funding round:
Series A
$4M
Series A (2010): $4M, investors not publicly disclosed
What's next for MetronomX?
The substantial enterprise-level funding MetronomX has garnered, particularly the recent strategic investment, positions the company for accelerated growth and development. This capital infusion is expected to fuel the advancement of its lead drug candidates, MNX-100 and MNX-200, through critical clinical trial phases. The company's commitment to socially responsible innovation and its focus on addressing unmet needs in cancer treatment suggest a strategic trajectory aimed at bringing novel therapies to patients and solidifying its market presence in the oncology sector.
See full MetronomX company page
